Collplant Biotechnologies Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.2001
- Today's High:
- $7.41
- Open Price:
- $7.3
- 52W Low:
- $4.27
- 52W High:
- $13.97
- Prev. Close:
- $7.3
- Volume:
- 1356
Company Statistics
- Market Cap.:
- $85.50 million
- Book Value:
- 2.997
- Revenue TTM:
- $299000
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $13.64 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -24.01%
- Return on Equity TTM:
- -43.73%
Company Profile
Collplant Biotechnologies Ltd had its IPO on 2018-01-30 under the ticker symbol CLGN.
The company operates in the Healthcare sector and Biotechnology industry. Collplant Biotechnologies Ltd has a staff strength of 73 employees.
Stock update
Shares of Collplant Biotechnologies Ltd opened at $7.3 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.2 - $7.41, and closed at $7.22.
This is a -1.1% slip from the previous day's closing price.
A total volume of 1,356 shares were traded at the close of the day’s session.
In the last one week, shares of Collplant Biotechnologies Ltd have increased by +5.09%.
Collplant Biotechnologies Ltd's Key Ratios
Collplant Biotechnologies Ltd has a market cap of $85.50 million, indicating a price to book ratio of 2.7123 and a price to sales ratio of 162.9776.
In the last 12-months Collplant Biotechnologies Ltd’s revenue was $299000 with a gross profit of $13.64 million and an EBITDA of $-16021000. The EBITDA ratio measures Collplant Biotechnologies Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Collplant Biotechnologies Ltd’s operating margin was 0% while its return on assets stood at -24.01% with a return of equity of -43.73%.
In Q1, Collplant Biotechnologies Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 81.3%.
Collplant Biotechnologies Ltd’s PE and PEG Ratio
- Forward PE
- 4.9237
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.42 per share while it has a forward price to earnings multiple of 4.9237 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Collplant Biotechnologies Ltd’s profitability.
Collplant Biotechnologies Ltd stock is trading at a EV to sales ratio of 121.9774 and a EV to EBITDA ratio of -4.4162. Its price to sales ratio in the trailing 12-months stood at 162.9776.
Collplant Biotechnologies Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $35.76 million
- Total Liabilities
- $2.92 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $145000
- Dividend Payout Ratio
- 0%
Collplant Biotechnologies Ltd ended 2024 with $35.76 million in total assets and $0 in total liabilities. Its intangible assets were valued at $35.76 million while shareholder equity stood at $29.89 million.
Collplant Biotechnologies Ltd ended 2024 with $0 in deferred long-term liabilities, $2.92 million in other current liabilities, 4955000.00 in common stock, $-93437000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $26.53 million and cash and short-term investments were $26.53 million. The company’s total short-term debt was $527,000 while long-term debt stood at $0.
Collplant Biotechnologies Ltd’s total current assets stands at $29.06 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $731000.00 compared to accounts payable of $885000.00 and inventory worth $1.78 million.
In 2024, Collplant Biotechnologies Ltd's operating cash flow was $0 while its capital expenditure stood at $145000.
Comparatively, Collplant Biotechnologies Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.22
- 52-Week High
- $13.97
- 52-Week Low
- $4.27
- Analyst Target Price
- $16.92
Collplant Biotechnologies Ltd stock is currently trading at $7.22 per share. It touched a 52-week high of $13.97 and a 52-week low of $13.97. Analysts tracking the stock have a 12-month average target price of $16.92.
Its 50-day moving average was $6.75 and 200-day moving average was $7.98 The short ratio stood at 2.98 indicating a short percent outstanding of 0%.
Around 1016% of the company’s stock are held by insiders while 1223.4% are held by institutions.
Frequently Asked Questions About Collplant Biotechnologies Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel’s Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.